The Lung Cancer Cohort Consortium (LC3) was formed in 2010 to carry out collaborative research on lung cancer risk and etiology as a signature project of the United States National Cancer Institute (NCI) Cohort Consortium. The consortium primarily includes longitudinal population cohort studies from around the world, but also includes some lung cancer screening cohorts. With more than 3 million longitudinally followed research participants and 70 000 incident lung cancer cases included in the centralized database, the LC3 provides an unprecedented resource to study lung cancer risk in North America, Europe, Asia, the Middle East, and Oceania. The centralized LC3 database, hosted at the International Agency for Research on Cancer (IARC), includes harmonized baseline and follow-up information on all research participants, as well as focused biomarker data on up to 10 000 research participants that have been generated under specific grants.
The LC3 is committed to facilitating the use of LC3 data by the wider research community for research within its scientific mandate.
The LC3 mandate: to facilitate collaborative research on the following topics: